ANZCTR search results

Brief description of the study purpose This study is being conducted to determine whether adding a targeted internal radiation treatment called OncoSil™ (Phosphorus-32 microparticles) to standard chemotherapy improves outcomes for patients with locally advanced pancreatic cancer. Who is it for? You may be eligible for this study if you are male or female aged 18 or older, with unresectable locally advanced pancreatic adenocarcinoma as per National Comprehensive Cancer Network (NCCN) guidelines, fit to commence first-line standard FOLFIRINOX therapy and have a life expectancy greater than 3 months. Study details Those who are eligible will be randomly allocated to either receive standard FOLFIRINOX chemotherapy alone or chemotherapy plus a single endoscopic ultrasound-guided OncoSil™ implantation into the tumour. Participants will be followed over time with regular scans, blood tests, and health assessments to monitor tumour response, side effects, and quality of life. It is hoped that the results from this study will help determine whether this combined treatment approach is more effective and safe than chemotherapy alone.

Is the ‘Fit for Purpose’ intervention clinically and cost-effective for improving pain and physical function in older adults with knee OA who have had TKR surgery? This research project will test the effectiveness of a new physiotherapy intervention called ‘Fit for Purpose’ Training provided in early post-surgical care (~3 months) after TKR surgery. This new intervention was co-designed with patients and clinicians and aims to improve long-term pain and function outcomes after TKR surgery. The goal of this research is to better understand long-term (1 year) outcomes after TKR surgery and if we can improve these long-term outcomes. Specifically, we aim to test whether our new Fit for Purpose physiotherapy intervention is more effective than an educational intervention.

The study aims to effectiveness the impact of light therapy, known as photobiomodulation (PBM), on recipients of allogeneic haematopoietic stem cell transplant (alloHSCT) in the prevention of oral mucositis. This work is important because oral mucositis is common, painful, costly, and a major cause of suffering during transplant care. PBM is a simple, quick, non invasive therapy with international guideline support but limited local use. Who is it for? You may be eligible for this study if you are an adult who is receiving allogeneic haematopoietic stem cell transplant at the Royal Adelaide Hospital. Study details Participants in this study will either receive current standard practice in the prevention and treatment of oral mucositis, or, they will receive current practice plus light therapy. Light therapy sessions will occur daily from the day of first chemotherapy session until 2 days after receiving the allogeneic haematopoietic stem cell transplant. Treatment sessions will take approximately 5 minutes and occur while the participant is an inpatient at the Royal Adelaide Hospital. Participants will then be followed up to determine if they are experiencing oral mucositis and data will be collected from medical records. The primary outcome of the study will be the incidence and duration of severe oral mucositis. It will also measure patient wellbeing, pain, nutrition, bacteraemia rates, hospital stay length, and how easily staff can adopt the treatment. It is hoped that this study will help provide clearer evidence on PBM’s real world effectiveness, data on costs and quality of life benefits, and practical information related to its implementation.

The purpose of this study is to test if a medical device called a SpiroNose® can be used to diagnose health conditions that cause respiratory symptoms, lung imaging abnormalities and sleep disorders. Who is it for? You may be eligible for this study if you are an adult who is either: 1. attending clinic for assessment of your respiratory symptoms or sleep or lung conditions, or 2. in the community and do not currently experience any respiratory symptoms or have lung abnormalities or any sleep conditions Study details Participants will be asked to perform a breath test on a device called a SpiroNose® . This breath test involves gentle breathing into the mouthpiece of the SpiroNose® and takes about 1 minute. Participants will also be asked to complete a few questionnaires immediately after the breath test. One questionnaire asks the participant what they thought about the SpiroNose® breath test; other questionnaires are used to collect clinical information such as the diagnosis of their current condition, if their condition has been diagnosed, and other health issues they may have. All participants will be followed up with a telephone call 2 months later to check if health status has changed, if medications have changed or if they have had more medical tests. The study coordinator will check their medical records for the final diagnosis up to 24 months after the breath test. Participants attending the respiratory clinic for assessment or management of lung cancer may be invited by their treating physician to perform a second SpiroNose® breath test after surgery or treatment as part of their clinical care. It is hoped that this research study will help determine if the SpiroNose® device can be used to identify participants with medical conditions such as asthma, chronic obstructive pulmonary disease, lung cancer, bronchiectasis, interstitial lung abnormalities, cardiac failure, obstructive sleep apnoea and narcolepsy.

To evaluate if a doctor-pharmacist collaborative prescribing model of care (intervention) produces fewer medication prescribing errors compared to usual care (medical prescribing - control) with regards to the prescribing for patients’ admission medication orders, and the appropriateness of surgical antibiotic prophylaxis orders, in a perioperative setting within a non-tertiary hospital. Consented patients were randomised into an intervention or control group. Based on the elective surgery determined by the physician, the intervention group had their admission medication chart prescribed by the prescribing pharmacist. This included intentional withholding, or medication amendments to the patients usual home medications during the perioperative period, as well as prescribing any applicable surgical antibiotic prophylaxis.

Brief description of the study purpose The CAPITALL Study aims to determine whether introducing blinatumomab earlier in the treatment of children and adolescents with B-cell acute lymphoblastic leukaemia (B-ALL) can achieve similar levels of leukaemia clearance and cure, while potentially reducing the overall treatment burden compared with the standard chemotherapy regime. Who is it for? You may be eligible for this study if you are under 18 years of age who are newly diagnosed with B-cell acute lymphoblastic leukaemia (B-ALL), including certain infant cases without KMT2A rearrangement. Study details All those who are eligible will be treated according to their risk group (standard, medium, or high risk) using established clinical, genetic, and molecular criteria. Most participants (excluding standard-risk patients) will receive blinatumomab following initial induction therapy. Blinatumomab is an approved medication given as a continuous intravenous infusion over 28 days, with 1–3 treatment blocks depending on the participant’s treatment plan. This is a single-arm study, meaning all participants receive study treatment, and there is no randomisation. Study results will be compared to historical patient data from previous trials and standard treatment regimens. Participants will undergo regular assessments, including blood tests and molecular testing (e.g. minimal residual disease testing), to measure how effectively the treatment clears leukaemia cells. It is hoped that the results from this study will help demonstrate whether earlier use of blinatumomab can maintain treatment effectiveness while reducing treatment intensity, potentially improving outcomes and quality of life for children with B-ALL.

1. This study is a clinical trial in healthy adults to understand how safe SLTE-1009 is and how the body handles it. 2. SLTE-1009 is an investigational medicine that affects certain brain pathways and is being developed for possible use in Migraine patients. 3. Participants will receive either a single Intravenous dose or multiple subcutaneous doses of the study drug or a placebo, with careful monitoring throughout the study. 4. Doctors will closely monitor participants for side effects, 5. The study uses small groups, step-by-step dosing, and close medical supervision to help ensure participant safety.

This study will look at the Feasibility of delivering Physiotherapy and Dietetics intervention via a hybrid format (online and face to face) for patients with end stage knee osteoarthritis referred to a public hospital for surgical opinion. The study will focus on patients with a Body Mass Index >35kg/m2. We think it is feasible to deliver this intervention in a hybrid format for this patient group. The secondary aim is to determine if this combined treatment is effective in this format. We will look at weight loss and functional improvement to determine this.

De-escalation skills are highly regarded by staff and patients as a tactical approach to Occupational Violence (OV) prevention and response. De-escalation refers to a range of communication techniques (non-verbal and verbal communication) to help a person (e.g. patients, consumers) regain control of their emotions (e.g. agitation, distress, frustration, anger) and assist them to calm reducing the likelihood and severity of OV by defusing emotions before they escalate to aggression or violence. This study we will evaluate a VR-based de-escalation training of Emergency Department staff.

Mother–Infant Dialectical Behaviour Therapy (MIDBT) is a specialist group programme that supports mothers with borderline personality disorder to develop skills for managing emotions and cope with the challenges of parenting. Although the programme has shown significant benefits, many mothers are unable to attend face-to-face groups because of geographical location, limited transport options or other practical barriers. This study aims to evaluate a telehealth version of the MIDBT programme and compare it with the existing face-to-face programme and a wait-list control group. The study will assess whether telehealth MIDBT improves borderline personality symptoms, depression, anxiety, post-traumatic disorder symptoms, parental stress, child social-emotional functioning and health-related quality of life. It will also explore how acceptable and practical the telehealth programme is and gather participants’ views and experiences. We predict that telehealth MIDBT will lead to greater improvements in mental health, parental stress and child social-emotional functioning compared with the wait-list group, while also being acceptable. We also expect that outcomes for telehealth MIDBT will be comparable to those achieved with the existing face-to-face MIDBT programme.